Overview

Regentis is developing cartilage and bone repair products based on its Gelrin™ Platform Technology as described below. These products are in various stages of preclinical development and are not yet approved for marketing:

• GelrinC - a promising new therapeutic approach for repair of localized focal cartilage defects. The ultimate aim of GelrinC is restoration of normal joint function by regenerating hyaline cartilage in the defect site, with complete integration of the regenerated cartilage with the surrounding cartilage and underlying bone. Read more...
  
  
• GelBone - a void filling matrix for bone regeneration designed to be used in osseous injuries. GelBone is designed to be injected directly into a bone defect using minimally invasive surgical techniques. Read more...